Latest News
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
INO earnings call for the period ending September 30, 2024.
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
INO earnings call for the period ending June 30, 2024.
As a part of the annual Russell index rebalancing, here are five stocks set to join the Russell Microcap Index this year, which analysts have tagged with consensus ‘buy’ ratings.
Better Buy: Inovio Pharmaceuticals vs. Novavax
Both biotechs have been struggling for a while, but there might be some hope for them.
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
INO earnings call for the period ending March 31, 2024.
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Can the biotech succeed after a string of failures?
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript
INO earnings call for the period ending December 31, 2023.
Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript
INO earnings call for the period ending September 30, 2023.
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript
INO earnings call for the period ending June 30, 2023.
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European...
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Present at the 2023 Jefferies Healthcare Conference
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Inovio Pharmaceuticals (INO) Q1 2023 Earnings Call Transcript
INO earnings call for the period ending March 31, 2023.
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the...
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.
Why Inovio Pharmaceuticals' Shares Jumped on Thursday
The company will present an abstract for its Ebola vaccine booster this month.
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Why Shares of Inovio Pharmaceuticals Were Down Tuesday
The biotech stock, still reeling from a failed clinical trial, hit a 52-week low.